bispecific antibodies

windmill turbines in the Netherlands
Biotech

Windward generates $200M with Novo Holdings, OrbiMed in tow

Novo Holdings-backed Windward is circling in $200 million and offering up to $970 million biobucks for rights to a clinical-stage antibody.
Gabrielle Masson Jan 10, 2025 10:02am
Armadillo girdled lizard biting its own tail in a defensive pose

Ouro launches with $120M and a clinical-stage T-cell engager

Jan 10, 2025 6:00am
Graphic of two hands shaking under a red and purple light

Candid adds another T-cell engager via $925M WuXi Biologics deal

Jan 7, 2025 8:42am
U turn turn around refocus pivot street sign

I-Mab pauses Sanofi-partnered prospect to focus on CLDN18.2

Jan 6, 2025 8:34am
Hundred dollar bills wrapped with a red bow under a Christmas tree

Candid unwraps 3 collabs to develop new T-cell engagers

Dec 16, 2024 11:59am
broken bone fracture break x ray skeleton

Angitia raises $120M series C to fund 3 musculoskeletal trials

Dec 11, 2024 9:40am